Kestra Medical Technologies CEO Webster sells $412,180 in stock

Kestra Medical Technologies CEO Brian Daniel Webster divested 15,000 shares of the company's stock on August 17, 2026. The transaction totaled $412,180, with shares exchanged at a weighted average price of $27.4787. This sale adhered to a Rule 10b5-1 trading plan adopted by Webster in September 2025. KMTS stock had been trading near its 52-week high of $30.00, having increased by 78% over the past year.

After the sale, Webster retained 460,215 shares directly. As President and CEO, he also serves on the company's Board of Directors. Kestra Medical Technologies, valued at $1.63 billion, remains unprofitable with a loss of $2.43 per share over the past year. Despite strong revenue growth in the fiscal fourth quarter of 2026, the company missed earnings expectations, posting an EPS loss of $0.67 compared to the estimated loss of $0.58.

Market analysts have shown a mixed interest in Kestra Medical Technologies, with JPMorgan and Oppenheimer initiating coverage with a bullish Overweight and Perform rating, respectively, while Wolfe Research raised its price target to $30.00 and maintained an Outperform rating.